FDG PET对接受同步放化疗的局部晚期头颈部鳞状细胞癌的预后影响:系统综述与Meta分析
该系统综述与Meta分析纳入25项研究共2223例局部晚期头颈部鳞状细胞癌患者,评估基线FDG PET代谢参数与预后的关联。高代谢肿瘤体积(MTV)与更差的总生存(汇总RR 1.86,95%CI 1.08-3.21)、无进展生存(汇总RR 1.81,95%CI 1.14-2.89)和局部区域控制(汇总RR 3.49,95%CI 1.65-7.35)显著相关;SUVmax与任何结局指标均无统计学显著关联。由于异质性大且缺乏标准化方法,无法确定最佳截断值。
要点
- 高基线MTV与更差OS、PFS和LRC显著相关,是唯一对结局有显著影响的代谢变量。
- SUVmax与OS、PFS、LRC均无统计学显著关联。
- 因异质性大(I²>50%)且方法未标准化,无法确定不利预后的累积阈值。
核心结论
- FDG PET在局部晚期头颈部鳞状细胞癌中具有预后相关性,治疗前MTV是唯一对患者结局有显著影响的代谢变量。
- 由于异质性和缺乏标准化方法,无法就最佳截断值得出确定性结论。
研究设计与样本
- 系统综述与Meta分析,纳入25项研究共2223例接受局部晚期疾病标准治疗的患者。
- 分析基线FDG PET半定量代谢参数与疗效结局指标关联的相对风险(RR)估计。
主要发现
- 最常见原发肿瘤部位为口咽(1150/2223例,51.7%)。
- 多数患者为III/IV期(1709/1799例,94.9%;4项研究无信息)并接受标准同步放化疗(1562/2009例,77.7%;仅1项研究无信息)。
- 分别有11、8和4项独立研究提供基线FDG PET指标与总生存(OS)、无进展生存(PFS)和局部区域控制(LRC)关联的RR估计。
- 高治疗前代谢肿瘤体积(MTV)与更差OS显著相关(汇总RR 1.86,95%CI 1.08-3.21)。
- 高治疗前MTV与更差PFS显著相关(汇总RR 1.81,95%CI 1.14-2.89),与更差LRC显著相关(汇总RR 3.49,95%CI 1.65-7.35)。
关键数值与推荐
- 高治疗前MTV与更差OS相关:汇总RR 1.86,95%CI 1.08-3.21。
- 高治疗前MTV与更差PFS相关:汇总RR 1.81,95%CI 1.14-2.89。
- 高治疗前MTV与更差LRC相关:汇总RR 3.49,95%CI 1.65-7.35。
- SUVmax与任何结局指标均无统计学显著关联。
- 汇总指标异质性大(I²>50%),无法定义不利预后的累积阈值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 汇总指标存在大异质性(I²>50%)。
- 缺乏标准化方法,无法就最佳截断值得出确定性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Evidence is conflicting on the prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in head and neck squamous cell carcinoma. The aim of our study was to determine the impact of semiquantitative and qualitative metabolic parameters on the outcome in patients managed with standard treatment for locally advanced disease. METHODS: A systematic review of the literature was conducted. A meta-analysis was performed of studies providing estimates of relative risk (RR) for the association between semiquantitative metabolic parameters and efficacy outcome measures. RESULTS: The analysis included 25 studies, for a total of 2,223 subjects. The most frequent primary tumour site was the oropharynx (1,150/2,223 patients, 51.7%). According to the available data, the majority of patients had stage III/IV disease (1,709/1,799, 94.9%; no information available in four studies) and were treated with standard concurrent chemoradiotherapy (1,562/2,009 patients, 77.7%; only one study without available information). A total of 11, 8 and 4 independent studies provided RR estimates for the association between baseline FDG PET metrics and overall survival (OS), progression-free survival (PFS) and locoregional control (LRC), respectively. High pretreatment metabolic tumour volume (MTV) was significantly associated with a worse OS (summary RR 1.86, 95% CI 1.08-3.21), PFS (summary RR 1.81, 95% CI 1.14-2.89) and LRC (summary RR 3.49, 95% CI 1.65-7.35). Given the large heterogeneity (I2 > 50%) affecting the summary measures, no cumulative threshold for an unfavourable prognosis could be defined. No statistically significant association was found between SUVmax and any of the outcome measures. CONCLUSION: FDG PET has prognostic relevance in the context of locally advanced head and neck squamous cell carcinoma. Pretreatment MTV is the only metabolic variable with a significant impact on patient outcome. Because of the heterogeneity and the lack of standardized methodology, no definitive conclusions on optimal cut-off values can be drawn.
引用
- Bonomo P, Merlotti A, Olmetto E, et al. What is the prognostic impact of FDG PET in locally advanced head and neck squamous cell carcinoma treated with concomitant chemo-radiotherapy? A systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2018. PMID: 29948105. doi:10.1007/s00259-018-4065-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。